Evidence of increased adverse event risk with systemic corticosteroid (SCS) use led patient management guidelines to embrace SCS-sparing treatment strategies. This study was conducted to describe time trends in SCS prescriptions and their relation to National Health Service (NHS) availability of SCS-sparing therapies.
|Number of pages||3|
|Publication status||Published - 19 Feb 2021|
|Event||BTS WINTER MEETING - Online|
Duration: 17 Feb 2021 → 20 Feb 2021
|Conference||BTS WINTER MEETING|
|Period||17/02/21 → 20/02/21|